Julie A Simpson 1,2,3; Leon Aarons 4; William E Collins 5; Geoffrey M Jeffrey 5; Nicholas J White 1,2; The natural progression of P.falciparum malaria:- Investigation of a historical cohort of syphilis patients treated with malariatherapy.
|
Timothy Goggin1,2Philippe Jacqmin4, Ronald Gieschke1,3, Goonaseelan (Colin) Pillai1,2, Eric Snoeck4, Pascal Girard4, Jean-Louis Steimer1,3. Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug.
|
Gordon Graham and Leon Aarons Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
|
L. Aarons, M. Karlsson, F. Mentré, A.V. Peer, F. Rombout, H. Schaefer, J.-L. Steimer, I. Trocóniz The role of modelling and simulation in the clinical development of anti-cancer agents
|
Philip Lowe Ph.D On mechanism based PK/PD modelling for direct drug-ligand binding systems
|
Fredrik Jonsson Physiologically based pharmacokinetic modeling in risk assessment -Development of Bayesian population methods
|
Vincent Duval and Mats O. Karlsson Influence of LOQ on the pharmacokinetics parameters after an IV bolus dose
|
Zingmark, Per-Henrik* Edenius, Charlotte* and Karlsson Mats O** Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis (MS)
|
E. N. Jonsson, F. Macintyre, I. James, W. Wild and S. Marshall A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
|
Lewis B Sheiner Dealing With Missing Data in Longitudinal Studies Through Modeling
|
Dave Lunn Graphical Models and Missing Data
|
NHG Holford1, S Bååthe 2, Mats Karlsson2 Auckland Bones and Summer Sun
|
Philippe Jacqmin1, Ronald Gieschke2,4, Paul Jordan2,4, Jean-Louis Steimer2,4, Timothy Goggin2,3, Goonaseelan (Colin) Pillai2,3, Eric Snoeck1, Pascal Girard1. Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model
|
J.G.Wright Forward selection and other recipes for disaster
|
Karlsson Mats, Jonsson Niclas and Zingmark Per-Henrik Models for sedation scores in acute stroke patients
|
Kimko, Hui C. Iron kinetics: when drug loss by sampling is critical in data analysis
|
Ivan Nestorov Sensitivity Analysis of PBPK and PK/PD Models
|
Joe Schafer Multiple Imputation for Missing-Data Problems
|
Paolo Vicini Integrated system models to understand disease status, progression and therapy: case studies
|
C. Laveille, C. Christin-Maitre*, C. Varin, Y. Tsouderos, and R. Jochemsen. Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of Estradiol (E2) in postmenopausal women
|
Ferdie Rombout LOQ, a relic of the past?
|